Subtype
Primary Central Nervous System Neoplasm
CI-CAN-00001432Explore in graph →
Non-malignant957 active trials5 approved drugs175 evidence items
- NCIt
- C102871
Loading cancer entity…
Subtype
CI-CAN-00001432Explore in graph →
Clinical trials
3,294 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00859040 | Monthly SOM230C for Recurrent or Progressive Meningioma | completed | Phase 2 | 34 | Patrick Y. Wen, MDOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT01866449 | Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme | completed | Phase 2 | 24 | University of UlmOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT02301364 |
| Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) |
| completed |
| Phase 2 |
| 4 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Oct 19, 2017 |
| clinicaltrials |
| NCT00045708 | A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2017 | clinicaltrials |
| NCT03310372 | Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme(TEMOFRAC) | completed | Phase 2 | 46 | Central Hospital, Nancy, FranceOTHER | 0 | Oct 17, 2017 | clinicaltrials |
| NCT01759810 | Proteome-based Personalized Immunotherapy of Glioblastoma | unknown | Phase 2 / Phase 3 | 60 | NeuroVita ClinicOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT02987010 | Phase 2 Study of IDH305 in Low Grade Gliomas | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | Oct 11, 2017 | clinicaltrials |
| NCT01310868 | Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma | completed | Phase 2 | 59 | University College, LondonOTHER | 1 | Oct 5, 2017 | clinicaltrials |
| NCT00575796 | Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs) | unknown | Phase 2 | 50 | The Hospital for Sick ChildrenOTHER | 1 | Sep 20, 2017 | clinicaltrials |
| NCT01508117 | Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients | terminated | Phase 2 | 1 | University of CincinnatiOTHER | 1 | Sep 19, 2017 | clinicaltrials |
| NCT00187486 | Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors | completed | Phase 2 | 66 | University of California, San FranciscoOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT03013387 | Dosimetry Guided PRRT With 90Y-DOTATOC | withdrawn | Phase 2 | 0 | Sue O'DorisioOTHER | 0 | Aug 25, 2017 | clinicaltrials |
| NCT00003460 | Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors(PNET) | completed | Phase 2 | 13 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00003469 | Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System | terminated | Phase 2 | 4 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00003470 | Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma(AA) | completed | Phase 2 | 27 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00003477 | Antineoplaston Therapy in Treating Children With Visual Pathway Glioma(VPG) | completed | Phase 2 | 12 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00003483 | Antineoplaston Therapy in Treating Patients With Meningioma | terminated | Phase 2 | 3 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT02852382 | The Effects of Scalp Block on Haemodynamic Response and Postoperative Pain in Posterior Fossa Surgery | completed | Phase 2 | 45 | Istanbul UniversityOTHER | 0 | Aug 22, 2017 | clinicaltrials |
| NCT00326872 | AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine | terminated | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2017 | clinicaltrials |
| NCT02029573 | Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma(ART) | completed | Phase 2 | 36 | King Fahad Medical CityOTHER_GOV | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00980343 | GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00727506 | BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma | completed | Phase 2 | 151 | Boehringer IngelheimINDUSTRY | 2 | Aug 15, 2017 | clinicaltrials |
| NCT00540722 | Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2017 | clinicaltrials |
| NCT01708174 | A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) | completed | Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 13 | Aug 11, 2017 | clinicaltrials |
| NCT01465347 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 59 | Diffusion Pharmaceuticals IncINDUSTRY | 1 | Jul 14, 2017 | clinicaltrials |
| NCT03212235 | Hypofractionated Radiation Therapy for Glioblastoma | unknown | Phase 2 | 58 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT00823797 | Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma | completed | Phase 2 | 45 | University of WashingtonOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT01290263 | Amgen 386 for Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01413438 | Bevacizumab With or Without Surgery for Adult Glioblastomas | withdrawn | Phase 2 | 0 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 0 | Jul 2, 2017 | clinicaltrials |
| NCT02848794 | Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma | unknown | Phase 1 / Phase 2 | 40 | The First People's Hospital of LianyungangOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT00112866 | Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme | terminated | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00392171 | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) | completed | Phase 2 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00424554 | Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) | completed | Phase 2 | 40 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00684567 | Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED) | completed | Phase 2 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT01310855 | Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma | terminated | Phase 2 | 38 | University College, LondonOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00345163 | A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)(BRAIN) | completed | Phase 2 | 167 | Genentech, Inc.INDUSTRY | 0 | May 16, 2017 | clinicaltrials |
| NCT00045734 | Imatinib Mesylate in Treating Patients With Recurrent Meningioma | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | May 15, 2017 | clinicaltrials |
| NCT00783393 | SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) | completed | Phase 2 | 32 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT00589706 | A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas | completed | Phase 2 | 11 | Drexel University College of MedicineOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01122901 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma | terminated | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | May 3, 2017 | clinicaltrials |
| NCT00706810 | Combination of Hydroxyurea and Verapamil for Refractory Meningiomas | completed | Phase 2 | 8 | University of UtahOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT02550249 | Neoadjuvant Nivolumab in Glioblastoma(Neo-nivo) | completed | Phase 2 | 29 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT00379080 | Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01268566 | A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 62 | MedImmune LLCINDUSTRY | 1 | Apr 6, 2017 | clinicaltrials |
| NCT00883298 | Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 30 | Center for Neurosciences, TucsonOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT00360828 | Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas | terminated | Phase 2 | 10 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT01280552 | A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) | completed | Phase 2 | 124 | Precision Life Sciences GroupINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT00459381 | Pazopanib in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Oct 27, 2017source: clinicaltrials